Caicun J. Zhou
Expertise in
12
conditions

Caicun J. Zhou

No.1800 Yuntai Road, 
Pudong, CN 
Expertise in
12
conditions
No.1800 Yuntai Road, 
Pudong, CN 

Overview

Caicun Zhou practices practicing medicine in Pudong, China.

Zhou is highly rated in 12 conditions, according to our data. Their clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Small Cell Lung Cancer (SCLC), and Lymphadenectomy.

They are actively involved in clinical research, co-authoring 585 peer reviewed articles and participating in 5 clinical trials.

Locations

No.1800 Yuntai Road, Pudong, 200120, China
Other Locations
No. 507, Zheng Min Road, Shanghai, 200433, China
No 1239 Siping Road, Shanghai, 200433, China
Zhengmin Road
Yangpu, 200433, China
Zheng Min Road, Shanghai, 200433, China
No. 1838, Xueyuan West Road, Wenzhou, 325027, China
Tongji University No. 507 Zhengmin Road, Shanghai, 200433, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)
A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2026
Intervention Type: Drug
Study Drugs: Durvalumab, Tremelimumab, Abraxane+Carboplatin, Gemcitabine+Cisplatin, Gemcitabine+Carboplatin, Pemetrexed+Carboplatin, Pemetrexed+Cisplatin
Study Phase: Phase 3
A Phase Ib/II Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With Advanced NSCLC
A Phase Ib/II Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With Advanced NSCLC
Enrollment Status: Completed
Publish Date: March 02, 2026
Intervention Type: Drug
Study Drug: AK112
Study Phase: Phase 1/Phase 2
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 3
An Open, Single-arm, Multi-center, Phase 2 Clinical Trial of Famitinib Combined With Epidermal Growth Factor Receptor (EGFR) Inhibitor HS-10296 in Patients With Advanced EGFR-mutant Non-Small Cell Lung Cancer (NSCLC)
An Open, Single-arm, Multi-center, Phase 2 Clinical Trial of Famitinib Combined With Epidermal Growth Factor Receptor (EGFR) Inhibitor HS-10296 in Patients With Advanced EGFR-mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Unknown
Publish Date: July 07, 2022
Intervention Type: Drug
Study Drugs: Famitinib, HS-10296
Study Phase: Phase 2
Single Arm Phase II Clinical Trial to Investigate the Efficacy and Safety of Apatinib as a Single Agent in Advanced NSCLC Who Failed to at Least Two Lines Systemic Treatment, or Were Not Amendable to Receive the Second-line Standard Therapy
Single Arm Phase II Clinical Trial to Investigate the Efficacy and Safety of Apatinib as a Single Agent in Advanced NSCLC Who Failed to at Least Two Lines Systemic Treatment, or Were Not Amendable to Receive the Second-line Standard Therapy
Enrollment Status: Unknown
Publish Date: August 18, 2017
Intervention Type: Drug
Study Drug: Apatinib Single Agent
Study Phase: Phase 2
View 4 Less Clinical Trials

585 Total Publications

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.
Journal: The New England journal of medicine
Published: May 29, 2026

Frequently Asked Questions about Caicun J. Zhou

Is Caicun J. Zhou a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Caicun J. Zhou is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Caicun J. Zhou participate in research or clinical trials?

Yes. Caicun J. Zhou has published 585 articles and abstracts on conditions like Lung Cancer. You can view a list of Caicun J. Zhou's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhou's expertise for a condition
ConditionClose
View All 46 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile